TB-500 Half-Life: What the Fragment Research Actually Shows

The TB-500 half-life question sounds straightforward until you separate the marketed fragment from the broader thymosin beta-4 research. Once you do, the timing story becomes clearer—and the takeaway more useful. Here's what the actual research shows.

The Fragment Question Comes First

Commercial TB-500 is best described as a short acetylated fragment of thymosin beta-4, not the full 43-amino-acid protein. The clearest scientific identification came from anti-doping research, which identified TB-500 as Ac-LKKTETQ—the 17-23 active-region fragment identified in TB-500 testing work. That distinction matters because half-life claims bounce between the fragment, the full protein, and general recovery practice as if they're interchangeable.

Where the Human Data Actually Points

The strongest human systemic data in this biology comes from full-length thymosin beta-4 studies, not the typical injected TB-500 fragment. The main example is RGN-352, an injectable full-length thymosin beta-4 tested for acute myocardial infarction with daily dosing for 3 days followed by weekly dosing for 4 more weeks ClinicalTrials.gov study record. Beyond that, the clearest published efficacy signal is actually quite different: a 0.1% thymosin beta-4 ophthalmic solution improved several dry-eye endpoints in a Phase 2 randomized trial randomized Phase 2 trial. That explains why the half-life question feels oddly slippery. The better human evidence belongs to full-length thymosin beta-4 in specific clinical applications, not the injected TB-500 fragment routine you mean. For a parallel look at how recovery-peptide enthusiasm can outpace solid evidence, BPC-157 dosage is worth reading.

• The fragment sold as TB-500 and full-length thymosin beta-4 should not be treated as the same pharmacokinetic story.
• Human trials exist for thymosin beta-4 products, but none establish a clear half-life for the marketed TB-500 fragment.
• The strongest published human benefit signals come from topical or defined clinical programs, not the typical recovery-vial use case.

Why Weekly Protocols Lean on Precedent, Not Pure PK

The weekly-spacing confidence around TB-500 comes largely from practice, community experience, and broader thymosin beta-4 biology rather than from a published human pharmacokinetic paper. When you search primary sources, you find fragment-identification work, equine administration studies, and human trials of other thymosin beta-4 forms—but not a modern peer-reviewed half-life study for the marketed fragment itself. The regulatory picture reinforces that gap: as of May 2026, the FDA is still reviewing TB-500 as a bulk substance under 503A compounding authority for wound healing, with discussion scheduled for the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting July 2026 committee agenda. If you're following the access and regulatory side, BPC-157, TB-500, and KPV Just Hit a Real FDA Access Milestone provides the most current context.

What This Means for Your Timing

So how long does TB-500 last? Long enough to justify the protocol conversation, but not well enough characterized for a definitive human pharmacokinetic answer. The strongest move is to treat fragment claims with appropriate caution, keep them separate from full thymosin beta-4 data, and align your expectations with the actual evidence. If your bigger question is whether recovery peptides show real promise, BPC-157 benefits is the next logical read once you've sorted the TB-500 timing question.